Characteristics of study and group participants
| . | Age at visit date, y (IQR) . | Duration of HIV infection*† . | Viral load, log10 copies/mL (IQR) . | CD4+ T-cell count, cells/mm3 (IQR) . | CD8+ T-cell count, cells/mm3 (IQR) . |
|---|---|---|---|---|---|
| Study A (n = 25, SCOPE cohort) | In y (IQR)* | ||||
| HAART (n = 10) | 39 (34-47) | 12 (8-14) | < 1.5 | 967 (432-996) | 1586 (1185-2265) |
| Prog. CD4 < 350 (n = 10) | 37 (31-46) | 12 (10-13) | 4.64 (4.26-5.01) | 265 (162-328) | 1227 (788-1611) |
| Neg (n = 5) | 31 (25-35) | NA | NA | NA | NA |
| Study B (n = 76, SCOPE cohort) | In y (IQR)* | ||||
| LTNP (n = 10) | 50 (46-53) | 16 (15-17) | 3.04 (1.93-3.45) | 814 (769-1037) | 1258 (1181-2184) |
| Controllers (n = 10) | 48 (44-51) | 16 (15-18) | < 1.5 | 747 (613-1034) | 962 (639-1133) |
| HAART (n = 14) | 51 (41-55) | 16 (11-21) | < 1.5 | 720 (658-830) | 857 (623-958) |
| Prog. CD4 < 350 (n = 14) | 41 (38-44) | 13 (10-16) | 4.65 (4.24-5.14) | 218 (179-260) | 1224 (1060-1599) |
| Prog. CD4 > 350 (n = 14) | 43 (37-47) | 8 (3-15) | 4.53 (4.42-4.72) | 504 (473-541) | 1325 (950-1801) |
| Neg (n = 14) | 33 (28-44) | NA | NA | NA | NA |
| Study C (n = 27, Options cohort) | In mo (IQR)† | ||||
| Group 1 (early, n = 9) | 37 (35-40) | 3.4 (2.6-4.2) | 3.51 (3.13-3.95) | 675 (534-756) | 836 (636-911) |
| Group 2 (early, n = 9) | 36 (34-43) | 3.1 (2.4-3.3) | 4.66 (4.33-4.79) | 528 (416-592) | 976 (640-1150) |
| Group 3 (early, n = 9) | 39 (34-42) | 2.8 (2.4-3.3) | 4.67 (3.99-4.88) | 592 (480-837) | 931 (660-1161) |
| Group 1 (late, n = 9) | 38 (35-41) | 14.1 (9.5-14.3) | 3.19 (2.95-3.38) | 702 (481-805) | 781 (630-920) |
| Group 2 (late, n = 9) | 37 (35-44) | 13.5 (10.6-14.3) | 4.92 (4.73-5.26) | 308 (253-437) | 974 (594-1102) |
| Group 3 (late, n = 9) | 40 (36-43) | 9.6 (8.5-10.9) | 4.61 (4.54-4.91) | 426 (404-707) | 896 (733-1094) |
| Study D (n = 26, SCOPE cohort) | In y (IQR)* | ||||
| HAART (n = 10) | 47 (38-54) | 11 (10-16) | < 1.5 | 560 (466-644) | 1451 (1396-1508) |
| Prog. CD4 < 350 (n = 16) | 45 (40-54) | 15 (10-18) | 4.29 (4.19-5.17) | 244 (139-394) | 889 (606-1199) |
| . | Age at visit date, y (IQR) . | Duration of HIV infection*† . | Viral load, log10 copies/mL (IQR) . | CD4+ T-cell count, cells/mm3 (IQR) . | CD8+ T-cell count, cells/mm3 (IQR) . |
|---|---|---|---|---|---|
| Study A (n = 25, SCOPE cohort) | In y (IQR)* | ||||
| HAART (n = 10) | 39 (34-47) | 12 (8-14) | < 1.5 | 967 (432-996) | 1586 (1185-2265) |
| Prog. CD4 < 350 (n = 10) | 37 (31-46) | 12 (10-13) | 4.64 (4.26-5.01) | 265 (162-328) | 1227 (788-1611) |
| Neg (n = 5) | 31 (25-35) | NA | NA | NA | NA |
| Study B (n = 76, SCOPE cohort) | In y (IQR)* | ||||
| LTNP (n = 10) | 50 (46-53) | 16 (15-17) | 3.04 (1.93-3.45) | 814 (769-1037) | 1258 (1181-2184) |
| Controllers (n = 10) | 48 (44-51) | 16 (15-18) | < 1.5 | 747 (613-1034) | 962 (639-1133) |
| HAART (n = 14) | 51 (41-55) | 16 (11-21) | < 1.5 | 720 (658-830) | 857 (623-958) |
| Prog. CD4 < 350 (n = 14) | 41 (38-44) | 13 (10-16) | 4.65 (4.24-5.14) | 218 (179-260) | 1224 (1060-1599) |
| Prog. CD4 > 350 (n = 14) | 43 (37-47) | 8 (3-15) | 4.53 (4.42-4.72) | 504 (473-541) | 1325 (950-1801) |
| Neg (n = 14) | 33 (28-44) | NA | NA | NA | NA |
| Study C (n = 27, Options cohort) | In mo (IQR)† | ||||
| Group 1 (early, n = 9) | 37 (35-40) | 3.4 (2.6-4.2) | 3.51 (3.13-3.95) | 675 (534-756) | 836 (636-911) |
| Group 2 (early, n = 9) | 36 (34-43) | 3.1 (2.4-3.3) | 4.66 (4.33-4.79) | 528 (416-592) | 976 (640-1150) |
| Group 3 (early, n = 9) | 39 (34-42) | 2.8 (2.4-3.3) | 4.67 (3.99-4.88) | 592 (480-837) | 931 (660-1161) |
| Group 1 (late, n = 9) | 38 (35-41) | 14.1 (9.5-14.3) | 3.19 (2.95-3.38) | 702 (481-805) | 781 (630-920) |
| Group 2 (late, n = 9) | 37 (35-44) | 13.5 (10.6-14.3) | 4.92 (4.73-5.26) | 308 (253-437) | 974 (594-1102) |
| Group 3 (late, n = 9) | 40 (36-43) | 9.6 (8.5-10.9) | 4.61 (4.54-4.91) | 426 (404-707) | 896 (733-1094) |
| Study D (n = 26, SCOPE cohort) | In y (IQR)* | ||||
| HAART (n = 10) | 47 (38-54) | 11 (10-16) | < 1.5 | 560 (466-644) | 1451 (1396-1508) |
| Prog. CD4 < 350 (n = 16) | 45 (40-54) | 15 (10-18) | 4.29 (4.19-5.17) | 244 (139-394) | 889 (606-1199) |
IQR indicates interquartile range; Neg, HIV-seronegative subjects; HAART, chronically HIV-infected subjects under highly active antiretroviral therapy; LTNP, long-term nonprogressors; Controllers, chronically HIV-infected “elite” viral controllers; Prog. CD4 > 350 and Prog. CD4 < 350, chronically HIV-infected progressors with CD4 counts > 350 or < 350, respectively; and NA, not available.
Years of self-reported HIV diagnosis (SCOPE cohort).
Months from estimated infection date (OPTION cohort).